Cyclerion Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cyclerion Therapeutics Inc 's ROA in the second quarter of 2026?
Cyclerion Therapeutics Inc recorded a cumulative net loss of $-7 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -74.89%.

However, within the Healthcare sector 679 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3980, from total ROA ranking in the first quarter of 2026 at 4374.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-26.16 %	-13.63 %	-33.1 %	-26.9 %	-15.32 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-7	-5	-4	-2	-2
Return On Assets (TTM)	-74.89 %	-55.14 %	-35.62 %	-19.74 %	-16.09 %
CYCN's Total Ranking	# 3980	# 4374	# 3599	# 3598	# 3863
Total Assets (TTM) in million	7	9	10	10	9
Seq. Total Assets Change	-18.65 %	-14.82 %	-4.13 %	11.15 %	-4.84 %
Seq. Net Income Change	-	-	-	-	-

CYCN's 5 Years Annual ROA >> Back to CYCN Management Effectiveness >> Compare CYCN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 310
Sector	# 680
Overall	# 4120

Return On Assets Statistics
High	Average	Low
24.06 %	-64.43 %	-178.38 %
(Jun 30 2024)		(Jun 30 2023)

News about Cyclerion Therapeutics Inc Return on Assets ROA

Cyclerion Therapeutics: Strategic Shifts and Leadership Overhaul Aim to Revitalize Growth Amid Financial Challenges,

Cyclerion Therapeutics: Navigating Growth Amidst ChallengesIn a proactive move aimed at invigorating growth and repositioning itself in the competitive pharmaceutical landscape, Cyclerion Therapeutics Inc. has recently emphasized leveraging its legacy soluble guanylate cyclase (sGC) stimulator portfolio to generate immediate revenues. This strategic initiative comes on the heels of their latest financial disclosures, which illustrate an interesting juxtaposition: the company secured a return on assets (ROA) of 6.81% in the third quarter of 2024—a significant improvement over its historical average ROA of -61.9%. Despite this improvement, the company s ROA fell compared to the previous quarter, which raises questions about its sustainability in light of a growing net income. To further compound this analysis, it’s important to note that Cyclerion s total ranking within the healthcare sector fell dramatically—from 31st to 520th—indicating an increasing struggle to keep pace with competitors. This shift is particularly notable, as the healthcare sector is home to 62 other companies with stronger ROA, illustrating Cyclerion s challenges in maintaining investor confidence.As Cyclerion navigates these turbulent waters, its share price has taken a hit, currently reflecting a decline of 2.73% over the past 90 days. Such trends create a cloudy outlook for investors looking for reassurance in the company s potential turnaround strategy, particularly as Cyclerion aims to capitalize on its sGC stimulator assets.

Cyclerion Therapeutics Appoints Dr. Regina Graul as President to Lead Rebuilding Efforts

Cyclerion Therapeutics Inc, a leading pharmaceutical company, has recently announced the appointment of Regina Graul, Ph.D., as its new President. Dr. Graul, with her extensive experience in drug making, RandD portfolio leadership, and company strategy, is expected to play a vital role in the rebuilding process of Cyclerion.
With over two decades of experience in the pharmaceutical industry, Dr. Graul brings a wealth of knowledge and expertise to her new position at Cyclerion. Her appointment comes at a critical time for the company, as it seeks to overcome recent setbacks and chart a path towards future success.

Financial Statements
Cyclerion Therapeutics Inc 's Assets	$ 7 million	CYCN's Balance sheet
Cyclerion Therapeutics Inc 's Income	$ -2 million	Quarterly CYCN's Income Statement
CYCN's Income by Division		See CYCN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	2.75 %	-20.29 %	5.07 %	-69.55 %	-21.13 %
Total Assets in million	15	15	19	18	59
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-4	-3	-5	-44	-52
Annual Return On Assets	-23.01 %	-20.48 %	-28.11 %	-247.35 %	-88.25 %

CYCN's 5 Years Annual ROA >> Back to CYCN Management Effectiveness >> Compare CYCN ROA to its Competitors

More Return On Assets Ratios
CYCN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CYCN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CYCN's Competitors
Subscribers only: Roa for Cyclerion Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CYCN's Customers

You may also want to know
CYCN's Roi	CYCN's Inventory Turnover Ratio	CYCN's Growth Rates	CYCN's Dividend Comparisons
	CYCN's Profitability Ratios	CYCN's Asset Turnover Ratio	CYCN's Dividend Growth
CYCN's Roe	CYCN's Valuation Ratios	CYCN's Financial Strength Ratios	CYCN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-13T21:11:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.